AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Zymeworks Inc. (ZYME)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

14.00

-0.82 (-5.53%)

At close: Feb 20, 2025, 3:59 PM

13.50

-3.57%

After-hours: Feb 20, 2025, 04:25 PM EST

undefined% (undefined)

Bid	12.9
Market Cap	964.28M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.49
PE Ratio (ttm)	-9.4
Forward PE	n/a
Analyst	Hold

Ask	14.63
Volume	228,310
Avg. Volume (20D)	443,745
Open	14.72
Previous Close	14.82
Day's Range	13.89 - 14.72
52-Week Range	7.97 - 17.70
Beta	undefined

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 28, 2017

Employees 294

Stock Exchange NYSE

Ticker Symbol ZYME

Website https://www.zymeworks.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for ZYME stock is "Hold." The 12-month stock price forecast is $18, which is an increase of 28.57% from the latest price.

Buy 66.67%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Zymeworks Inc. is scheduled to release its earnings on Mar 5, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+9.46%

Zymeworks shares are trading higher after JP Morga... Unlock content with Pro Subscription

News

1 month ago · seekingalpha.com

3 Biotech Stocks With Notable Insider Buying

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-ca...

1 month ago · zacks.com

Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade

The mean of analysts' price targets for Zymeworks (ZYME) points to a 41.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...

2 months ago · seekingalpha.com

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks ...

2 months ago · https://thefly.com

Zymeworks upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Zymeworks to Overweight from Neutral with an $18 price target.